Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | HMGCR | P04035 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9916134 | 0.98 | NAAA (0.46) | NAAAEPHX1HTTHMGCRCYP2C19 | |
| SCHEMBL16784766 | 0.93 | APOBEC3A (0.37) | NAAAEPHX1HTTHMGCRCYP19A1 | |
| SCHEMBL17589175 | 0.85 | ALDH1A1 (0.33) | NAAAHMGCRCYP19A1APOBEC3AAPOBEC3G | |
| SCHEMBL17550540 | 0.83 | NAAA (0.46) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL15681467 | 0.83 | CYP19A1 (0.44) | HMGCRCYP19A1FKBP1A | |
| SCHEMBL2734982 | 0.83 | HMGCR (0.37) | NAAAEPHX1HTTHMGCRCYP19A1 | |
| SCHEMBL132134 | 0.83 | EPHX1 (0.47) | NAAAEPHX1HTTHMGCRCYP2C19 | |
| SCHEMBL685983 | 0.82 | NAAA (0.42) | NAAAEPHX1HTTCYP2C19CYP19A1 | |
| SCHEMBL16591000 | 0.82 | HMGCR (0.36) | NAAAEPHX1HTTHMGCRCYP19A1 | |
| SCHEMBL15681469 | 0.82 | HMGCR (0.41) | HMGCRFKBP1AAPOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859183-B2 | N-acyl-β-lactam derivative, macromolecular compound, and photoresist composition | KURARAY CO., LTD. (JP) | 2014-10-14 | — | — | US | disclosed |
| US-8753794-B2 | N-acyl-β-lactam derivative, macromolecular compound, and photoresist composition | KURARAY CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20140038106-A1 | N-ACYL-B-LACTAM DERIVATIVE, MACROMOLECULAR COMPOUND, AND PHOTORESIST COMPOSITION | KURARAY CO., LTD. (JP) | 2014-02-06 | — | — | US | disclosed |
| US-8486606-B2 | Acrylate derivative, haloester derivative, polymer compound and photoresist composition | KURARAY CO., LTD. (JP) | 2013-07-16 | — | — | US | disclosed |
| US-20120148954-A1 | N-ACYL-B-LACTAM DERIVATIVE, MACROMOLECULAR COMPOUND, AND PHOTORESIST COMPOSITION | KURARAY CO., LTD. (JP) | 2012-06-14 | — | — | US | disclosed |
| US-20110117497-A1 | ACRYLATE DERIVATIVE, HALOESTER DERIVATIVE, POLYMER COMPOUND AND PHOTORESIST COMPOSITION | KURARAY CO., LTD. (JP) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148954-A1 | N-ACYL-B-LACTAM DERIVATIVE, MACROMOLECULAR COMPOUND, AND PHOTORESIST COMPOSITION | COASY, ARCN1, CLTB | NAAA 326/4885EPHX1 4678/4885HTT 3362/4885 |
| US-20110117497-A1 | ACRYLATE DERIVATIVE, HALOESTER DERIVATIVE, POLYMER COMPOUND AND PHOTORESIST COMPOSITION | ARCN1, H1-10, RER1 | NAAA 2974/4885EPHX1 2464/4885HTT 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.